The encyclopedia · R&D & Science · Strategic decision · 1999–2026
NICE prices a year of healthy life so the NHS can ration
NICE values a year of perfect health, then funds any drug whose extra benefit costs under £20,000–£30,000 per such year.
National Institute for Health and Care Excellence
the move
The UK NHS is a single payer with a fixed budget, so it literally cannot afford every medicine that works. The naive response is the hidden ration that most systems use: no explicit rule, and access decided piecemeal by whoever argues hardest.
NICE, created in 1999, picked the opposite route. It measures a treatment's benefit on a common scale — the quality-adjusted life year — then divides cost by benefit to get an incremental cost-effectiveness ratio. Drugs priced under £20,000–£30,000 per QALY gained are funded; expensive ones must cut their price.
One consistent number does the heavy work. It puts rationing in public, forces manufacturers to negotiate on price rather than on spin, and gives clinicians a defensible reason a drug was not approved.
The threshold rarely moved for twenty years; in 2026 the UK raised it to £25,000–£35,000 per QALY, expected to bring three to five more drugs into funding each year.
why it works
- A QALY translates survival and pain into one number so different diseases can compete fairly.
- A published threshold makes a rationing decision auditable instead of political.
- Because price is endogenous to appraisal, the rule bends manufacturers toward lower prices.
- The same decision rule across all drugs gives consistent, predictable outcomes.
what transfers
Rationing is unavoidable; it can be hidden or done by rule. Publishing what a QALY is worth turns a back-room decision into a public standard and nudges makers to price below the line.
what came after
NICE's threshold became the model copied by assessment agencies in dozens of countries. It stayed at £20,000–£30,000 for two decades, drew criticism that it under-values innovation, and in April 2026 was raised to £25,000–£35,000 per QALY as part of a UK–US pharma trade agreement.
references
- NICE's new cost-effectiveness threshold: Significance, consequences, and unanswered questions
- A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals
spotted an error? The archive wants to know.